Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug –drug interaction study in patients with ALK  + advanced tumors

ConclusionCeritinib is a strong CYP3A inhibitor and a weak CYP2C9 inhibitor. These findings should be reflected as actionable clinical recommendations in the prescribing information for ceritinib with regards to concomitant medications whose pharmacokinetics may be altered by ceritinib.

Source: Cancer Chemotherapy and Pharmacology - January 4, 2021 Category: Cancer & Oncology Source Type: research